Polymorph form II of tanaproget
Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.
1. An isolated polymorph form II of tanaproget having:
(a) an X-ray diffraction peak pattern comprising peaks at 2θ of about 6.0°, 8.3°, 12.0°, 21.4°, and 23.4°; and
(b) a differential scanning calorimetry thermogram having a T onset of about 219° C.
2. The isolated polymorph form II according to claim 1 , wherein said thermogram lacks an endotherm peak of about 230° C.
3. An isolated polymorph form II of tanaproget having an X-ray diffraction pattern of FIG. 1 or a differential scanning calorimetry thermogram of FIG. 2 .
4. An isolated and micronized form of 5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-y1)-1-methyl-1H-pyrrole-2-carbonitrile polymorph form II which has a median particle size less than about 20 μm; wherein polymorph form II of tanaproget has:
(a) X-ray diffraction peak pattern comprising peaks at 2θ of about 6.0°, 8.3°, 12.0°, 21.4°, and 23.4°; and
(b) a differential scanning calorimetry thermogram having a T onset of about 219° C.
5. A pharmaceutical composition comprising isolated polymorph form II of tanaproget and a pharmaceutically acceptable carrier; wherein polymorph form II of tanaproget has:
(a) X-ray diffraction peak pattern comprising peaks at 2θ of about 6.0°, 8.3°, 12.0°, 21.4°, and 23.4°; and
(b) a differential scanning calorimetry thermogram having a T onset of about 219° C.